[Current status of neoadjuvant chemotherapy for advanced esophageal cancer].

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Since reported in the JCOG9907 trial, neoadjuvant chemotherapy prior to surgery has become the standard treatment for advanced (Stage II/III) esophageal cancers. However, more powerful neoadjuvant chemotherapy is required for the treatment of locally advanced cases or cases involving multiple lymph node metastases. At our institute, DCF therapy (docetaxel, cisplatin, and 5-fluorouracil) is administered selectively for the treatment of patients with far-advanced esophageal cancer. We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012. FP therapy (cisplatin and 5-fluorouracil) was administered to 43 patients, and DCF therapy to 7 patients who had far-advanced esophageal cancer. All patients treated with DCF therapy experienced grade 3 and 4 adverse events. With the exception of 1 patient, all patients who received DCF therapy could undergo curative surgery. DCF therapy could become an effective preoperative chemotherapy.

Original languageEnglish
Title of host publicationGan to kagaku ryoho. Cancer & chemotherapy
Pages1612-1614
Number of pages3
Volume40
Edition12
Publication statusPublished - 2013

Fingerprint

Esophageal Neoplasms
Drug Therapy
Therapeutics
docetaxel
Fluorouracil
Cisplatin
Thorax
Lymph Nodes
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tanabe, S., Shirakawa, Y., Maeda, N., Katsube, R., Ohara, T., Sakurama, K., ... Fujiwara, T. (2013). [Current status of neoadjuvant chemotherapy for advanced esophageal cancer]. In Gan to kagaku ryoho. Cancer & chemotherapy (12 ed., Vol. 40, pp. 1612-1614)

[Current status of neoadjuvant chemotherapy for advanced esophageal cancer]. / Tanabe, Shunsuke; Shirakawa, Yasuhiro; Maeda, Naoaki; Katsube, Ryoichi; Ohara, Toshiaki; Sakurama, Kazufumi; Noma, Kazuhiro; Fujiwara, Toshiyoshi.

Gan to kagaku ryoho. Cancer & chemotherapy. Vol. 40 12. ed. 2013. p. 1612-1614.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tanabe, S, Shirakawa, Y, Maeda, N, Katsube, R, Ohara, T, Sakurama, K, Noma, K & Fujiwara, T 2013, [Current status of neoadjuvant chemotherapy for advanced esophageal cancer]. in Gan to kagaku ryoho. Cancer & chemotherapy. 12 edn, vol. 40, pp. 1612-1614.
Tanabe S, Shirakawa Y, Maeda N, Katsube R, Ohara T, Sakurama K et al. [Current status of neoadjuvant chemotherapy for advanced esophageal cancer]. In Gan to kagaku ryoho. Cancer & chemotherapy. 12 ed. Vol. 40. 2013. p. 1612-1614
@inbook{c945fb4b463e433ea071beb2e4dccf0f,
title = "[Current status of neoadjuvant chemotherapy for advanced esophageal cancer].",
abstract = "Since reported in the JCOG9907 trial, neoadjuvant chemotherapy prior to surgery has become the standard treatment for advanced (Stage II/III) esophageal cancers. However, more powerful neoadjuvant chemotherapy is required for the treatment of locally advanced cases or cases involving multiple lymph node metastases. At our institute, DCF therapy (docetaxel, cisplatin, and 5-fluorouracil) is administered selectively for the treatment of patients with far-advanced esophageal cancer. We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012. FP therapy (cisplatin and 5-fluorouracil) was administered to 43 patients, and DCF therapy to 7 patients who had far-advanced esophageal cancer. All patients treated with DCF therapy experienced grade 3 and 4 adverse events. With the exception of 1 patient, all patients who received DCF therapy could undergo curative surgery. DCF therapy could become an effective preoperative chemotherapy.",
author = "Shunsuke Tanabe and Yasuhiro Shirakawa and Naoaki Maeda and Ryoichi Katsube and Toshiaki Ohara and Kazufumi Sakurama and Kazuhiro Noma and Toshiyoshi Fujiwara",
year = "2013",
language = "English",
volume = "40",
pages = "1612--1614",
booktitle = "Gan to kagaku ryoho. Cancer & chemotherapy",
edition = "12",

}

TY - CHAP

T1 - [Current status of neoadjuvant chemotherapy for advanced esophageal cancer].

AU - Tanabe, Shunsuke

AU - Shirakawa, Yasuhiro

AU - Maeda, Naoaki

AU - Katsube, Ryoichi

AU - Ohara, Toshiaki

AU - Sakurama, Kazufumi

AU - Noma, Kazuhiro

AU - Fujiwara, Toshiyoshi

PY - 2013

Y1 - 2013

N2 - Since reported in the JCOG9907 trial, neoadjuvant chemotherapy prior to surgery has become the standard treatment for advanced (Stage II/III) esophageal cancers. However, more powerful neoadjuvant chemotherapy is required for the treatment of locally advanced cases or cases involving multiple lymph node metastases. At our institute, DCF therapy (docetaxel, cisplatin, and 5-fluorouracil) is administered selectively for the treatment of patients with far-advanced esophageal cancer. We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012. FP therapy (cisplatin and 5-fluorouracil) was administered to 43 patients, and DCF therapy to 7 patients who had far-advanced esophageal cancer. All patients treated with DCF therapy experienced grade 3 and 4 adverse events. With the exception of 1 patient, all patients who received DCF therapy could undergo curative surgery. DCF therapy could become an effective preoperative chemotherapy.

AB - Since reported in the JCOG9907 trial, neoadjuvant chemotherapy prior to surgery has become the standard treatment for advanced (Stage II/III) esophageal cancers. However, more powerful neoadjuvant chemotherapy is required for the treatment of locally advanced cases or cases involving multiple lymph node metastases. At our institute, DCF therapy (docetaxel, cisplatin, and 5-fluorouracil) is administered selectively for the treatment of patients with far-advanced esophageal cancer. We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012. FP therapy (cisplatin and 5-fluorouracil) was administered to 43 patients, and DCF therapy to 7 patients who had far-advanced esophageal cancer. All patients treated with DCF therapy experienced grade 3 and 4 adverse events. With the exception of 1 patient, all patients who received DCF therapy could undergo curative surgery. DCF therapy could become an effective preoperative chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84897018623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897018623&partnerID=8YFLogxK

M3 - Chapter

C2 - 24393865

AN - SCOPUS:84897018623

VL - 40

SP - 1612

EP - 1614

BT - Gan to kagaku ryoho. Cancer & chemotherapy

ER -